



Nanotechnologies for the Life Sciences

Edited by Challa Kumar

 WILEY-VCH

# Nanomaterials for Cancer Therapy



**NtLS** 

*Nanotechnologies for the Life Sciences*  
Volume 6

## **Nanomaterials for Cancer Therapy**

*Edited by*  
*Challa S. S. R. Kumar*

1st Edition



**WILEY-  
VCH**

WILEY-VCH Verlag GmbH & Co. KGaA

#### **The Editor of this Book**

Dr. Challa S. S. R. Kumar  
The Center for Advanced Microstructures  
and Devices (CAMD)  
Louisiana State University  
6980 Jefferson Highway  
Baton Rouge, LA 70806  
USA

#### **Cover**

Cover design by G. Schulz based on  
micrograph courtesy of M. Heldal,  
Department of Biology, University of  
Bergen, Norway  
(Superparamagnetic Dynabeads® by Dynal  
Bead Based Separations, a part of  
Invitrogen Corporation)

■ All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

#### **Library of Congress Card No.:** applied for **British Library Cataloguing-in-Publication Data:**

A catalogue record for this book is available from the British Library.

#### **Bibliographic information published by Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

© 2006 WILEY-VCH Verlag GmbH & Co.  
KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.  
Printed on acid-free paper.

**Typesetting** Asco Typesetter, Hong Kong  
**Printing** Strauss GmbH, Mörlenbach  
**Binding** Litges & Dopf Buchbinderei GmbH,  
Heppenheim  
**Cover Design** Grafik-Design Schulz,  
Fußgönheim

**ISBN-13:** 978-3-527-31386-0

**ISBN-10:** 3-527-31386-9

*Nanotechnologies for the*

*Life Sciences*

*Volume 6*

**Nanomaterials for Cancer  
Therapy**

*Edited by*

*Challa S. S. R. Kumar*

## Related Titles

Kumar, C. S. S. R. (ed.)

### ***Nanotechnologies for the Life Sciences (NtLS)***

**Book Series**

Vol. 1

#### **Biofunctionalization of Nanomaterials**

385 pages with 153 figures

Hardcover

ISBN 3-527-31381-8

Vol. 2

#### **Biological and Pharmaceutical Nanomaterials**

400 pages with 160 figures

Hardcover

ISBN 3-527-31382-6

Vol. 3

#### **Nanosystem Characterization Tools in the Life Sciences**

413 pages with 178 figures

Hardcover

ISBN 3-527-31383-4

Vol. 4

#### **Nanodevices for the Life Sciences**

approx. 400 pages with approx. 210 figures

Hardcover

ISBN 3-527-31384-2

Vol. 5

#### **Nanomaterials – Toxicity, Health and Environmental Issues**

approx. 400 pages with approx. 100 figures

2006

Hardcover

ISBN 3-527-31385-0

zur Hausen, H.

### **Infections Causing Human Cancer**

2006

Hardcover

ISBN 3-527-31056-8

Debatin, K.-M., Fulda, S. (eds.)

### **Apoptosis and Cancer Therapy**

**From Cutting-edge Science to Novel Therapeutic Concepts**

2006

Hardcover

ISBN 3-527-31237-4

Holland, E. C. (ed.)

### **Mouse Models of Cancer**

2004

Hardcover

ISBN 0-471-44460-X

Stuhler, G., Walden, P. (eds.)

### **Cancer Immune Therapy**

**Current and Future Strategies**

Hardcover

ISBN 0-527-30441-X

Goodsell, D. S.

### **Bionanotechnology**

**Lessons from Nature**

2004

Hardcover

ISBN 0-471-41719-X

Niemeyer, C. M., Mirkin, C. A. (eds.)

### **Nanobiotechnology**

**Concepts, Applications and Perspectives**

2004

Hardcover

ISBN 3-527-30658-7

## Preface

Even five years into the new millennium, cancer continues to torment humanity as the second leading cause of death with 10.9 million newly diagnosed cases worldwide in the year 2005 alone. Despite new discoveries of drugs and treatment combinations as evidenced by reports of close to 200,000 experimental studies on mice, two million scientific publications and an annual spending of around 15 billion US dollars world wide, the mortality rate due to cancer did not change in the past five to six decades. Therefore, there is still a strong need for a paradigm shift in the approach to cancer diagnosis and therapy. The advent of nanotechnological revolution offers an opportunity to achieve this paradigm shift. Since the biological processes in general and those that lead to cancer in particular occur at the nanoscale, there is a great opportunity for nanotechnologists to treat cancer at an as early stage as possible. Several innovative nanoscale constructs have been demonstrated to radically change cancer therapy with capabilities to deliver large doses of chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. They have also shown great promise in enabling rapid and sensitive detection of single cancer cells and cancer-related molecules. Reports of these investigations are being published in a very broad range of journals spanning several traditional disciplines. It is becoming difficult for researchers to gather all the available information on 'Cancer Nanotechnology'. I am, therefore, pleased to share with you, again on behalf of dedicated team of researchers in cancer nanotechnology, two volumes of the ten volume series on nanotechnologies for the life sciences specifically dedicated to cancer. The first of these two volumes, sixth in the series, that is being presented to you here is dedicated to cancer therapy and is aptly titled as "*Nanomaterials for Cancer Therapy*."

The book is divided into eleven chapters encompassing a number of therapeutic approaches in cancer treatment through use of a variety of nanomaterials. It begins with a chapter reviewing the progress that has been made to date in utilization of conventional chemotherapeutic drug nanoparticles for cancer treatment. The chapter *Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment* contributed by Loredanna Serpa from the University of Turin, Italy, is an up to date review of literature on advances being made in cancer treatment through use of nanoparticle formulations containing conventional chemotherapeutic drugs such as doxorubicin, cisplatin, paclitaxel and other drugs. Moving from conventional anticancer

drugs to conventional therapies that are being affected by nanotechnological tools, the second chapter starts with fundamental aspects of Photo Dynamic Therapy (PDT) that has been found to be promising in selectively treating tumors as well as metastasis without affecting the surrounding healthy tissue. The chapter *Nanoparticles for Photodynamic Therapy of Cancer*, written by Florence Delie and her team from the Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Geneva, Switzerland, provides an in-depth analysis of how nanoparticles, with special emphasis on polymeric biodegradable ones, are being developed to improve the conventional approaches to PDT. Continuing on a similar theme of improving conventional therapies, Yoshinobu Fukumori and co-workers from Kobe Gakuin University in Japan provide a general background on neutron capture therapy (NCT), a new radiotherapy that differs from the conventional radiotherapies, in the third chapter. This is followed by the authors reviewing more specifically both gadolinium neutron capture therapy (GdNCT) and boron neutron capture therapy (BNCT) with reference to use of nanomaterials. The remainder of the chapter *Nanoparticles for Neutron Capture Therapy of Cancer* provides a detailed account of the authors' experiences in developing Gd-containing lipid nanoemulsions and chitosan nanoparticles to demonstrate the usefulness of nanoparticle technology in NCT. Addressing a different facet of NCT, the fourth chapter entitled *Nanovehicles and High Molecular Weight Delivery Agents for Boron Neutron Capture Therapy* focuses on various high molecular weight (HMW) agents consisting of macromolecules and nanovehicles such as monoclonal antibodies, dendrimers, liposomes, dextrans, polylysine, avidin and folic acid, epidermal and vascular endothelial growth factors (EGF and VEGF) as delivery vehicles for introducing boron atoms. In it, Gong Wu, Rolf F. Barth, Weilian Yang, Robert Lee, Werner Tjarks, Marina V. Backer and Joseph M. Backer from the Department of Pathology at Ohio State University in Columbus, USA, have done a remarkable job in describing procedures for introducing boron atoms into HMW agents in addition to providing information on their chemical properties, bio-distribution based on in vivo studies, delivery across the blood brain barrier and various routes of their administration. Overall, the work reported in chapters three & four is very valuable and exciting not only from the scientific point of view, but also from the commercial point of view as recently clinical BNCT trials mainly for brain tumors were carried out in Japan.

Switching gears from earlier parts of the book where applications of nanotechnology to already well established treatments for cancer are presented, the rest of the chapters describe 'non-traditional' and innovative approaches completely based on nanotechnology that are being investigated for cancer therapy. Christoph Alexiou and Roland Jurgons from the Policlinic for otorhinolaryngological illnesses of Friedrich-Alexander University, Erlangen-Nuremberg, Germany, contributed the fifth chapter, *Local Cancer Therapy with Magnetic Drug Targeting using Magnetic Nanoparticles*, in which they review current literature on the use of magnetic nanoparticles in biomedicine in general and local chemotherapies, focusing especially on regional cancer therapy, in particular. In the sixth chapter, *Nanomaterials for Controlled Release of Anticancer Agents*, the team lead by Do Kyung Kim at the

Massachusetts Institute of Technology, Cambridge, USA, has done a remarkable job in capturing nuances of nanotechnologies, particularly those based on polymeric nanomaterials, being developed for controlled release of anticancer agents. In this chapter, the authors discuss various design aspects, theoretical models and kinetics of controlled release of anticancer drugs. The seventh chapter on the other hand provides a much broader perspective to cancer therapy using nanomaterials by providing a critical analysis of various approaches. While the chapter starts with a description of the tools of nanoparticle technology that can be used to treat cancer, it goes a step further in critically reviewing and discussing the advantages and drawbacks of nanoparticles for the targeted delivery of anticancer agents to defined cells of human cancers. The chapter entitled *Critical Analysis of Cancer Therapy using Nanomaterials* contributed by Lucienne Juillerat-Jeanneret from the University Institute of Pathology in Lausanne, Switzerland, concludes the section with a final section that describes the author's own design of how an ideal nanoparticulate system should be for the targeted treatment of human cancers.

Treating cancer using heat has been known for a long time as cells are known to undergo apoptosis when exposed to temperatures around 40 °C. Thermotherapy, as it is called, as performed using conventional approaches has several drawbacks. In the eighth chapter, *Nanoparticles for Thermotherapy*, a team of cancer specialists lead by Andreas Jordan describe, based on their own experience, how some of these drawbacks are being overcome using magnetic nanoparticles. The chapter is particularly valuable as the team from the Center of Biomedical Nanotechnology (CBN), Berlin, Germany, share their experience in conducting the first ever clinical trials with thermotherapy using magnetic nanoparticles. Moving conceptually to a more elegant approach, the ninth chapter entitled *Ferromagnetic Filled Carbon Nanotubes as Novel and Potential Containers for Anticancer Treatment Strategies* explores the feasibility of different applications using magnetic multi-walled CNTs (MWCNTs) more specifically as heat mediators for hyperthermia of solid tumors. While authors Ingolf Mönch et al. from the Leibniz Institute for Solid State and Materials Research in Dresden, Germany, are upbeat about potential opportunities in the use of different types of functionalized MWCNTs, they restrict their review to only those that are novel and those that have benefits specifically in the treatment of prostate cancer.

Several types of nanomaterials are currently being investigated for targeted delivery of anticancer agents and there is a need for understanding the pros and cons of using these different types of nanomaterials. Chapter ten written by Yong Zhang and Dev K. Chatterjee from the Division of Bioengineering at the National University of Singapore provides a platform for comparing the efficacy of different types of nanomaterials for targeted delivery. The chapter, *Liposomes, Dendrimers and other Polymeric Nanoparticles for Targeted Delivery of Anticancer Agents – A Comparative Study*, provides a unique perspective on different types of nanomaterials in general and three major types in particular that are gaining importance in this field. The chapter is a must for those interested in learning about background information on mechanisms and methods of targeting cancer cells. At this point of time, liposomes seem to have an edge over the other types of nanomaterials and in the au-



thor's own words, "the most exciting news is the performance of Epeius Biotechnologies Corporation's liposomal based active targeting system that delivers genetic material to treat several cancers, including pancreatic head carcinoma, which has one of the worst prognoses among all neoplasms." In the eleventh and final chapter of the book, the team lead by Jack-Michel Renoir from University of Paris-Sud in Châtenay-Malabry, France, focuses on the benefits of encapsulating a class of anticancer drugs known as antiestrogens (AEs) to improve antitumoral activities in vivo. In addition, the authors discuss in this chapter, *Colloidal Systems for the Delivery of Anticancer Agents in Breast Cancer and Multiple Myeloma*, the use of passive targeting through long-circulating drug delivery systems in different types of xenografts. They strongly believe that the approach using colloidal systems is promising not only for the administration of antiestrogens in estrogen-dependent breast cancers and multiple myeloma (MM), but also for the delivery of much more toxic anticancer agents such as taxol, thalidomide, bortezomib, VEGF inhibitors, farnesyltransferase inhibitors, histone transferase inhibitors and hsp90 inhibitors.

I am pleased by the broad range of useful information gathered by the dedicated contributors working in the area of cancer nanotechnology, and I am hoping that the book will be a guide for all those who wish to be associated with the growing field of 'Nanomaterials for Cancer Therapy'. I am indebted to all the authors for their extraordinary efforts and as always grateful to my employer, family, friends and Wiley VCH publishers for making this book a reality. I am thankful to you, the reader, who has taken time to join the journey with fellow cancer nanotechnologists. It will be my pleasure to hear back from you and I look forward to receiving your comments, suggestions and constructive criticism in order to make further improvements in the next editions of the book.

April 2006, Baton Rouge

Challa S. S. R. Kumar

## List of Contributors

### **Christoph Alexiou**

Dept. for Oto-Rhino-Laryngology, Head  
and Neck Surgery University  
Erlangen-Nuremberg  
Waldstr. 1  
91054 Erlangen  
Germany

### **Joseph M. Backer**

SibTech, Inc.  
705 North Mountain Road  
Newington, CT 06111  
USA

### **Marina V. Backer**

SibTech, Inc.  
705 North Mountain Road  
Newington, CT 06111  
USA

### **Rolf F. Barth**

Department of Pathology  
The Ohio State University  
129 Hamilton Hall, 1645 Neil Av.  
Columbus, OH 43210-1218  
USA

### **Dev K. Chatterjee**

Division of Bioengineering  
Faculty of Engineering  
National University of Singapore  
9 Engineering Drive 1  
Singapore 117576  
Singapore

### **Florence Delie**

Laboratory of Pharmaceutical Technology and  
Biopharmaceutics  
School of Pharmaceutical Sciences  
University of Geneva  
30, quai E. Ansermet  
1211 Geneva 4  
Switzerland

### **Jon Dobson**

Institute for Science & Technology in  
Medicine  
Keele University  
Thornburrow Drive, Hartshill  
Stoke-on-Trent, ST4 7QB  
United Kingdom

### **Elias Fattal**

University of Paris-Sud  
UMR CNRS 8612  
Faculty of Pharmacy  
5, rue J. B. Clément  
92296 Châtenay-Malabry  
France

### **Yoshinobu Fukumori**

Faculty of Pharmaceutical Sciences  
and Cooperative Research Center  
of Life Sciences  
Kobe Gakuin University  
Arise 518, Ikawadani-cho, Nishi-ku  
Kobe 651-2180  
Japan

### **Alicia El Haj**

Institute for Science & Technology in  
Medicine  
Keele University  
Thornburrow Drive, Hartshill  
Stoke-on-Trent, ST4 7QB  
United Kingdom

### **Hideki Ichikawa**

Faculty of Pharmaceutical Sciences  
and Cooperative Research Center  
of Life Sciences  
Kobe Gakuin University  
518 Arise, Ikawadani-cho, Nishi-ku  
Kobe 651-2180  
Japan

**Yun Suk Jo**

Institut des Biosciences Intégratives  
École Polytechnique Fédérale de Lausanne  
(EPFL)  
1015 Lausanne  
Switzerland

**Manfred Johannsen**

Department of Urology  
CCM, Charité – University Medicine  
Schumannstr. 20/21  
10117 Berlin  
Germany

**Andreas Jordan**

Center of Biomedical Nanotechnology (CBN)  
Spandauer Damm 130, Haus 30  
14050 Berlin  
Germany

**Lucienne Juillerat-Jeanneret**

University Institute of Pathology  
Bugnon 25  
1011 Lausanne  
Switzerland

**Roland Jurgons**

Dept. for Oto-Rhino-Laryngology, Head  
and Neck Surgery University  
Erlangen-Nuremberg  
Waldstr. 1  
91054 Erlangen  
Germany

**Do Kyung Kim**

Department of Electrical Engineering and  
Computer Science (EECS)  
Massachusetts Institute of Technology  
155 Mass Ave.  
Cambridge, MA 02139  
USA

**Robert Lee**

College of Pharmacy  
The Ohio State University  
129 Hamilton Hall, 1645 Neil Av.  
Columbus, OH 43210  
USA

**Albrecht Leonhardt**

Leibniz Institute for Solid State and Materials  
Research Dresden  
IFW Dresden  
Helmholtzstrasse 20  
01069 Dresden  
Germany

**Klaus Maier-Hauff**

Department of Neurosurgery  
Bundeswehrkrankenhaus  
Scharnhorststr. 13  
10115 Berlin  
Germany

**Sébastien Maillard**

University of Paris-Sud  
UMR CNRS 8612  
Faculty of Pharmacy  
5, rue J. B. Clément  
92296 Châtenay-Malabry  
France

**Véronique Marsaud**

University of Paris-Sud  
UMR CNRS 8612  
Faculty of Pharmacy  
5, rue J. B. Clément  
92296 Châtenay-Malabry  
France

**Axel Meye**

Department of Urology  
Technical University Dresden  
Fetscherstrasse 74  
01062 Dresden  
Germany

**Masahito Miyamoto**

Faculty of Pharmaceutical Sciences  
and Cooperative Research Center  
of Life Sciences  
Kobe Gakuin University  
518 Arise, Ikawadani-cho, Nishi-ku  
Kobe 651-2180  
Japan

**Ingolf Moench**

Leibniz Institute for Solid State and Materials  
Research Dresden  
IFW Dresden  
Helmholtzstrasse 20  
01069 Dresden  
Germany

**Mamoun Muhammed**

Materials Chemistry Division  
Royal Institute of Technology  
100 44 Stockholm  
Sweden

**Jack-Michel Renoir**

University of Paris-Sud  
UMR CNRS 8612  
Faculty of Pharmacy  
5, rue J. B. Clément  
92296 Châtenay-Malabry  
France

**Loredana Serpe**

Department of Anatomy  
University of Torino  
Via Pietro Giuria 13  
10125 Torino  
Italy

**Brigitte Solà**

UFR de Médecine  
CHU Côte de Nacre  
14032 Caen CEDEX  
France

**Werner Tjarks**

College of Pharmacy  
The Ohio State University  
129 Hamilton Hall, 1645 Neil Av.  
Columbus, OH 43210  
USA

**Hiroyuki Tokumitsu**

Faculty of Pharmaceutical Sciences  
and Cooperative Research Center  
of Life Sciences  
Kobe Gakuin University  
Arise 518, Ikawadani-cho, Nishi-ku  
Kobe 651-2180  
Japan

**Angelica Vargas**

Laboratory of Pharmaceutical Technology and  
Biopharmaceutics  
School of Pharmaceutical Sciences  
University of Geneva  
30, quai E. Ansermet  
CH-1211 Geneva 4  
Switzerland

**Gong Wu**

Department of Pathology  
The Ohio State University  
129 Hamilton Hall, 1645 Neil Av.  
Columbus, OH 43210  
USA

**Peter Wust**

Department of Radiology  
CVK, Charité – University Medicine  
Augustenburger Platz 1  
13353 Berlin  
Germany

**Weilian Yang**

Department of Pathology  
The Ohio State University  
129 Hamilton Hall, 1645 Neil Av.  
Columbus, OH 43210  
USA

**Magali Zeisser-Labouèbe**

Laboratory of Pharmaceutical Technology and  
Biopharmaceutics  
School of Pharmaceutical Sciences  
University of Geneva  
30, quai E. Ansermet  
1211 Geneva 4  
Switzerland

**Yong Zhang**

Division of Bioengineering  
Faculty of Engineering  
National University of Singapore  
9 Engineering Drive 1  
Singapore 117576  
Singapore

## Contents

**Preface** XIII

**List of Contributors** XVII

<b>1</b>	<b>Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment</b>	<b>1</b>
	<i>Loredana Serpe</i>	
1.1	Introduction	1
1.2	Cancer as Drug Delivery Target	2
1.3	Nanoparticles as Anticancer Drug Delivery System	4
1.3.1	Conventional Nanoparticles	5
1.3.2	Sterically Stabilized Nanoparticles	6
1.3.3	Actively Targetable Nanoparticles	8
1.3.4	Routes of Drug Nanoparticles Administration	10
1.4	Anticancer Drug Nanoparticles	12
1.4.1	Anthracyclines	12
1.4.1.1	Reverse of P-glycoprotein Mediated Multidrug Resistance of Cancer Cells to Doxorubicin	17
1.4.2	Antiestrogens	19
1.4.3	Anti-metabolites	20
1.4.4	Camptothecins	20
1.4.5	Cisplatin	21
1.4.6	Paclitaxel	21
1.4.7	Miscellaneous Agents	26
1.4.7.1	Arsenic Trioxide	26
1.4.7.2	Butyric Acid	26
1.4.7.3	Cystatins	26
1.4.7.4	Diethylenetriaminepentaacetic Acid	26
1.4.7.5	Mitoxantrone	27
1.4.8	Gene Therapy	27
	References	30

<b>2</b>	<b>Nanoparticles for Photodynamic Therapy of Cancer</b>	<b>40</b>
	<i>Magali Zeisser-Labou��be, Angelica Vargas, and Florence Delie</i>	
2.1	Introduction	40
2.2	Concept and Basis of Photodynamic Therapy and Photodetection	41
2.2.1	Mechanisms of Photodynamic Therapy and Photodiagnosis	41
2.2.2	Selective Tumor Uptake of Photosensitizers	43
2.2.3	Photosensitizers	45
2.2.3.1	Conventional Photosensitizers	45
2.2.3.2	New Entities	47
2.2.4	Photodynamic Therapy: Advantages and Limitations	51
2.2.5	Photosensitizer Formulations	53
2.3	Non-biodegradable Nanoparticles for Photodynamic Therapy	54
2.3.1	Metallic Nanoparticles	54
2.3.2	Ceramic Nanoparticles	55
2.3.3	Nanoparticles Made of Non-biodegradable Polymers	56
2.4	Biodegradable Polymeric Nanoparticles for Photodynamic Therapy	57
2.4.1	Preparation of Biodegradable Polymeric Nanoparticles	58
2.4.1.1	<i>In situ</i> Polymerization	58
2.4.1.2	Dispersion of a Preformed Polymer	59
2.4.1.3	“Stealth” Particles	60
2.4.1.4	Targeted Nanoparticles	60
2.4.2	<i>In Vitro</i> Relevance of Polymeric Nanoparticles in PDT on Cell Models	61
2.4.2.1	Photodynamic Activity of PS-loaded Nanoparticles	61
2.4.2.2	Uptake and Trafficking of Photosensitizers	66
2.4.3	<i>In Vivo</i> Relevance of Polymeric Nanoparticles in PDT	70
2.4.3.1	Biodistribution and Pharmacokinetics of Photosensitizers Coupled to Nanoparticles	70
2.4.3.2	Vascular Effects	71
2.4.3.3	<i>In Vivo</i> Efficacy on Tumor: Tumor Suppression Effects	73
2.4.3.4	Adverse Effects	74
2.5	Conclusions	75
	Acknowledgments	75
	Abbreviations	76
	References	77
<b>3</b>	<b>Nanoparticles for Neutron Capture Therapy of Cancer</b>	<b>87</b>
	<i>Hideki Ichikawa, Hiroyuki Tokumitsu, Masahito Miyamoto, and Yoshinobu Fukumori</i>	
3.1	Introduction	87
3.2	Principle of Neutron Capture Therapy of Cancer	88
3.3	Boron Neutron Capture Therapy	89
3.3.1	Boron Compounds	89
3.3.2	Delivery of Boron Using Nanoparticles	90
3.4	Approaches to GdNCT	93

3.4.1	Typical Research on GdNCT	94
3.4.2	Delivery of Gadolinium using Lipid Emulsion (Gd-nanoLE)	95
3.4.2.1	Preparation of Gd-nanoLE	95
3.4.2.2	Biodistribution of Gadolinium after Intraperitoneal Administration of Gd-nanoLE	98
3.4.2.3	Biodistribution of Gadolinium after Intravenous Administration of Gd-nanoLE	101
3.4.3	Delivery of Gadolinium using Chitosan Nanoparticles (Gd-nanoCPs)	104
3.4.3.1	Preparation of Gd-nanoCPs	105
3.4.3.2	Gd-DTPA Release Property of Gd-nanoCPs	107
3.4.3.3	Gd-DTPA Retention in Tumor Tissue after Intratumoral Injection	107
3.4.3.4	<i>In vivo</i> Growth Suppression of Experimental Melanoma Solid Tumor	108
3.4.3.5	Bioadhesion and Uptake of Gd-nanoCP in Three Different Cell Lines	109
3.5	Conclusions	113
	References	114

#### **4 Nanovehicles and High Molecular Weight Delivery Agents for Boron Neutron Capture Therapy 122**

*Gong Wu, Rolf F. Barth, Weilian Yang, Robert Lee, Werner Tjarks, Marina V. Backer, and Joseph M. Backer*

4.1	Introduction	122
4.1.1	Overview	122
4.1.2	General Background	123
4.2	General Requirements for Boron Delivery Agents	124
4.3	Low Molecular Weight Delivery Agents	124
4.4	High Molecular Weight Boron Delivery Agents	125
4.5	Dendrimer-related Delivery Agents	125
4.5.1	Properties of Dendrimers	125
4.5.2	Boronated Dendrimers Linked to Monoclonal Antibodies	126
4.5.2.1	Boron Clusters Directly Linked to mAb	126
4.5.2.2	Attachment of Boronated Dendrimers to mAb	129
4.5.3	Boronated Dendrimers Delivered by Receptor Ligands	127
4.5.3.1	Epidermal Growth Factors (EGF)	127
4.5.3.2	Folate Receptor Targeting Agents	129
4.5.3.3	Vascular Endothelial Growth Factor (VEGF)	129
4.5.4	Other Boronated Dendrimers	130
4.6	Liposomes as Boron Delivery Agents	130
4.6.1	Overview of Liposomes	130
4.6.2	Liposomal Encapsulation of Sodium Borocaptate and Boronophenylalanine	133
4.6.2.1	Boron Delivery by Non-targeted Liposomes	133
4.6.2.2	Liposomal Encapsulation of other Boranes and Carboranes	134

4.6.3	Boron Delivery by Targeted Liposomes	137
4.6.3.1	Immunoliposomes	137
4.6.3.2	Folate Receptor-targeted Liposomes	138
4.6.3.3	EGFR Targeted Liposomes	138
4.7	Boron Delivery by Dextrans	139
4.8	Other Macromolecules used for Delivering Boron Compounds	141
4.9	Delivery of Boron-containing Macromolecules to Brain Tumors	142
4.9.1	General Considerations	142
4.9.2	Drug-transport Vectors	142
4.9.3	Direct Intracerebral Delivery	142
4.9.4	Convection-enhanced Delivery (CED)	143
4.10	Clinical Considerations and Conclusions	144
	Acknowledgments	145
	References	145
<b>5</b>	<b>Local Cancer Therapy with Magnetic Drug Targeting using Magnetic Nanoparticles</b>	<b>156</b>
	<i>Christoph Alexiou and Roland Jurgons</i>	
5.1	Introduction	156
5.2	Local Chemotherapy	156
5.3	Magnetic Drug Delivery	158
5.3.1	<i>In Vitro</i> Applications	158
5.3.2	<i>In Vivo</i> Applications	159
	References	163
<b>6</b>	<b>Nanomaterials for Controlled Release of Anticancer Agents</b>	<b>168</b>
	<i>Do Kyung Kim, Yun Suk Jo, Jon Dobson, Alicia El Haj, and Mamoun Muhammed</i>	
6.1	Introduction	168
6.2	Nanoparticles for Biomedical Applications	170
6.2.1	First Generation Nanoparticles	171
6.2.2	Second Generation Nanoparticles	171
6.2.3	Advanced Generation Nanoparticles	172
6.3	Polymer Materials for Drug Delivery Systems	174
6.4	Design of Drug Delivery Vectors and Their Prerequisites	175
6.4.1	Polymeric Nanoparticles	175
6.4.2	Inorganic Nanoparticles	180
6.4.3	Metallic Nanoparticles	181
6.5	Kinetics of the Controlled Release of Anticancer Agents	181
6.5.1	Diffusion Model	182
6.5.2	Dissolution Model	183
6.5.3	Kinetics of the Indomethacin (IMC, 1-[ <i>p</i> -chlorobenzoyl]-2-methyl-5-methoxy-3-indoleacetic acid) Release	183
6.6	Controlled Release of Anticancer Agents	186



6.6.1	Alkylating Agents	186
6.6.1.1	Chlorambucil	187
6.6.1.2	Cyclophosphamide	187
6.6.1.3	Carmustine	188
6.6.2	Antimetabolic Agent	188
6.6.2.1	Cytarabine	188
6.6.2.2	Fluorouracil (FU)	189
6.6.2.3	Methotrexate	189
6.6.3	Anticancer Antibiotics	190
6.6.3.1	Actinomycin D	190
6.6.3.2	Bleomycin	190
6.6.3.3	Daunorubicin	191
6.7	Future Directions	191
	References	192
<b>7</b>	<b>Critical Analysis of Cancer Therapy using Nanomaterials</b>	<b>199</b>
	<i>Lucienne Juillerat-Jeanneret</i>	
7.1	Introduction	199
7.2	Anticancer Therapies	200
7.3	Characteristics of Nanoparticles for Cancer Therapy	202
7.3.1	Nanovectors	203
7.3.2	Biological Issues	205
7.3.3	Nanoparticle Targeting: Passive or Active	206
7.4	Nanovectors in Biomedical Applications: Drug Delivery Systems (DDS) for Cancer	207
7.4.1	Physicochemical Drug Delivery	208
7.4.2	Biological Drug Delivery	208
7.4.3	Chemical Drug Delivery	208
7.4.4	Nanoparticles for Anticancer Drug Delivery	209
7.4.4.1	Existing Systems	209
7.4.4.2	Systems under Development and Challenges	210
7.4.5	Nanoparticles for Drug Delivery in Clinical Use or under Clinical Evaluation	211
7.4.5.1	Doxorubicin Family	211
7.4.5.2	Paclitaxel (Taxol)	212
7.4.5.3	5-Fluorouracil	213
7.4.5.4	Tamoxifen	213
7.4.5.5	Cisplatin	213
7.4.5.6	Camptothecins	214
7.4.5.7	Methotrexate	214
7.4.6	New Experimental Drugs and Therapies	214
7.4.6.1	Proteins, Peptides, their Inhibitors and Antagonists	214
7.4.6.2	New Drugs	215
7.4.6.3	New Therapeutic Approaches: Photodynamic Therapy (PDT)	215